Pharmaceuticals Industry Trends United States - 2022

Market Monitor

  • USA
  • Chemicals/Pharma

15th March 2022

Robust growth expected in 2022

IT US pharma credit risk 2022

The US accounts for about 45% of the global pharmaceutical market and 22% of global production. US pharmaceuticals output and sales remain robust in 2022, driven by the ongoing global vaccination rollout and pent-up demand for essential and non-essential medical treatments. Margins of brand name drug producers have soared in 2021, resulting in strong cash flow. However, wholesalers/ distributors still trade on thin margins, despite growing sales. Some of them still have payments to make in connection with opioid-related lawsuits and litigations.

IT US pharma output 2022

While sector growth in 2022 and 2023 will be mainly driven by vaccinations, the ageing population will spur drug demand in the mid- and long-term. The decision of the Supreme Court to uphold the Affordable Care Act (Obamacare) also supports future growth prospects of the industry. However, pressure from legislature to reduce healthcare costs could rise again once the pandemic ends. This could affect investments, given the high R&D costs for producers.

Several pharmaceutical producers and distributors have taken advantage of historically low lending rates in order to pursue debt-financed acquisitions. Most of them used their strong cash flow to deleverage after larger takeovers, thereby maintaining their credit ratings. Payment duration in the industry can vary between 30 and 150 days. Major drug producers often use their leverage against suppliers to achieve longer payment terms and build cash flow. While non-payments are generally low in the industry, non-payment notifications have increased in the segment of small community-based pharmacies. Those businesses often compete against larger chains and face reimbursement pressures from public payers (e.g. Medicaid and Medicare).

Due to a government crackdown on opioids, a number of producers, distributors, and pharmacies heavily exposed to sales of such drugs were forced to close their businesses and/or file for bankruptcy between 2017 and 2020. Since then, business failures have returned to a very low level. Our underwriting stance is open for drug producers and distributors, while we are restrictive for small pharmacies due to increased payment delays.

 

Related documents

Disclaimer, no warranties and exclusion of liability

Atradius disclaims any representations or warranties of any kind, whether expressed or implied, including but not limited to implied warranties of merchantability and fitness for a particular purpose of (INCLUDING BUT NOT LIMITED TO) any information contained on or provided via this Web Site and/or any service described or promoted on this Web Site, including warranties with respect to infringement of any patent, copyright, or other rights of third parties. Atradius shall not be liable for any injury, loss, damage or expense arising out of any access to or use of this Web Site or any site linked to or from this Web Site, including, without limitation, any loss of profit, indirect, incidental or consequential loss. Atradius furthermore shall not be liable for persons, property damage or especially direct, indirect, incidental, consequential, immediate or subsequent (pecuniary) loss. While Atradius has used reasonable efforts in maintaining a virus-free Web Site, it declines any liability for persons, property damage or especially direct, indirect, incidental, consequential, immediate or subsequent (pecuniary) loss which may result from transmission or downloading of computer viruses. Atradius cannot be held liable for hardware damage, loss of data, alteration of data, or downtime.